Tasimelteon Tames Circadian Rhythms in Phase III Testing
By Catherine Shaffer
Tuesday, December 18, 2012
Advocates for the blind community are hailing new Phase III results for a drug that could provide relief from the debilitating symptoms of non-24-hour syndrome, a disorder in which the body is unable to reset its body clock to a 24-hour day, and which affects a majority of blind people.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.